Brochure

Leveraging Proprietary CDO Platforms

GettyImages-1294339670-lab-cleanroom-PPE-computer-team

Samsung Biologics has developed proprietary CDO platforms for bispecific antibodies, transient expression, developability assessment, cell line development, and modular glycosylation.

S-Dual™, an asymmetric bispecific antibody platform allows high yield and manufacturability. The platform has demonstrated high purity and lower residual impurities, with in vitro and in vivo assays showing comparable inhibition and tumor growth inhibition to reference antibodies. Furthermore, the S-DUAL™ bispecific antibodies have lower immunogenicity risk compared to trastuzumab and a positive control.

Their transient expression platform, S-CHOsient™, surpasses a commercial platform in terms of productivity and quality. It exhibits high productivity for monoclonal antibodies, Fc fusion proteins, and bispecific antibodies, ensuring qualified purity and intact formation.

Samsung Biologics also offers a developability assessment platform that efficiently assesses drug candidates based on specific criteria .The workflow includes various analytical techniques such as DSF, DLS, SE-HPLC, and CE-SDS, along with basic character study and stress confirmation.

Samsung Biologics' platforms aim to provide secure quality material provision for drug development, offering high-performing CHO-K1-based cell lines with improved productivity and viability. Learn how these robust platform offerings can help to optimize all stages of development and advance your project to clinic.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online